CLNN Stock Overview A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for Clene Historical stock prices Current Share Price US$4.72 52 Week High US$11.00 52 Week Low US$3.82 Beta 0.32 1 Month Change 13.19% 3 Month Change 7.03% 1 Year Change -18.62% 3 Year Change -94.10% 5 Year Change -97.75% Change since IPO -97.55%
Recent News & Updates Clene Inc. announced that it has received $10 million in funding Dec 21
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 15
Consensus EPS estimates fall by 11% Nov 14
New minor risk - Profitability Oct 28
Consensus revenue estimates decrease by 10% Oct 27 Clene Inc. announced that it has received $7.31006 million in funding Oct 10
See more updates Clene Inc. announced that it has received $10 million in funding Dec 21
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 15
Consensus EPS estimates fall by 11% Nov 14
New minor risk - Profitability Oct 28
Consensus revenue estimates decrease by 10% Oct 27 Clene Inc. announced that it has received $7.31006 million in funding Oct 10
Consensus revenue estimates increase by 11% Oct 03
New minor risk - Profitability Oct 02 Clene Inc. has completed a Follow-on Equity Offering in the amount of $3.499996 million. Oct 02
Clene Inc. announced that it expects to receive $3.810506 million in funding Oct 01
Clene Inc. has filed a Follow-on Equity Offering in the amount of $3.499996 million.
Price target decreased by 13% to US$48.00 Sep 16
Second quarter 2024 earnings released: US$1.06 loss per share (vs US$5.84 loss in 2Q 2023) Aug 08
Price target decreased by 8.8% to US$91.25 Aug 07
New major risk - Share price stability Aug 06
New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS Aug 06
Clene Inc. Regains Compliance with Nasdaq Listing Rule 5550(a)(2) for Continued Listing on Nasdaq Jul 27
Consensus revenue estimates increase by 16% Jul 17
Clene Inc. and Clene Nanomedicine Inc. Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8 in ALS Jul 12
Clene Inc. and Clene Nanomedicine Inc. Present Preliminary Data for CNM-Au8 as Potential Treatment for Rett Syndrome Jun 21
Clene Inc. and Clene Nanomedicine, Inc. Present Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8 30 mg Jun 18
Consensus revenue estimates fall by 30% May 15
First quarter 2024 earnings: EPS and revenues miss analyst expectations May 08
Clene Inc. and Clene Nanomedicine, Inc. Presented the Phase 2 VISIONARY-MS Long term Extension (LTE) Study Results at the 2024 American Academy of Neurology (AAN) Annual Meeting in Denver Apr 18
Clene Inc., Annual General Meeting, May 29, 2024 Apr 17
Clene Inc. Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8 Mar 16
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Mar 14
Clene Reports Significant Survival Benefit with Cnm-Au8® Treatment in Als Eap Compassionate Use Programs Feb 24 Clene Receives Notice from Nasdaq the Company Has Not Regained Compliance with the Minimum Bid Price Requirement Feb 01
Clene Inc. Reports Significant Improvement in Vision and Cognition with Cnm-Au8®? Treatment in Vision-MS Trial Jan 09
Price target decreased by 11% to US$5.00 Dec 23
Clene Inc. and Clene Nanomedicine Inc. Announce Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement in Neurodegenerative Diseases Dec 15
Independent Chairman of the Board recently bought US$103k worth of stock Nov 15
Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 09 Clene Inc. has filed a Follow-on Equity Offering in the amount of $15 million. Nov 08
New major risk - Revenue and earnings growth Nov 08
High number of new directors Oct 01
Clene Inc. Announces Executive Changes Sep 21
Consensus revenue estimates increase by 53%, EPS downgraded Aug 21
Price target decreased by 13% to US$5.83 Aug 17
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 14
Clene Receives Written Notice from The Nasdaq Stock Market LLC Regarding Non-Compliance with the Minimum Bid Price Requirement Aug 06
New minor risk - Market cap size Jul 26
New minor risk - Share price stability Jul 01
Independent Director recently bought US$253k worth of stock Jun 28
Clene Announces Publication of Phase 2 CNM-Au8® Clinical Data for the Treatment of ALS in LANCET’s eClinicalMedicine Jun 27
Price target decreased by 20% to US$6.71 Jun 22
Consensus revenue estimates increase by 21% Jun 21
New major risk - Shareholder dilution Jun 19
Clene’S Cnm-Au8® Shows Statistically Significant Difference in Plasma Neurofilament Light (Nfl) Levels in the Healey Als Platform Trial Jun 18 Clene Inc. has completed a Follow-on Equity Offering. Jun 17
Clene Receives Non-Compliance Notice From Nasdaq Jun 03
Consensus revenue estimates increase by 27% May 27
Consensus revenue estimates decrease by 53%, EPS upgraded May 19
First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind May 14
Price target decreased by 10% to US$8.57 Apr 11
Full year 2022 earnings: EPS and revenues exceed analyst expectations Mar 14
Price target increased by 10% to US$9.57 Mar 12
Clene Inc. Announces Resignation of Chidozie Ugwumba from the Board and All Committees Feb 18
Clene Inc. Reports New Data from the VISIONARY-MS Phase 2 Study in Multiple Sclerosis Demonstrating CNM-Au8(R) Treatment Improved Brain Neuronal Structural Integrity Feb 14
Clene Inc. Nanomedicine Reports Topline Results of Phase 2 COVID-19 Study of CNM-ZnAg Dec 28
Clene Inc. and Clene Nanomedicine Inc, Announce the Visionary-MS Trial Results Were Featured as A Platform Presentation by Professor Michael Barnett At the 14th Annual Singapore Pan-Asian Committee on Treatment and Research in Multiple Sclerosis Congress Nov 29
Third quarter 2022 earnings: EPS and revenues exceed analyst expectations Nov 08
Independent Chairman of the Board recently bought US$2.9m worth of stock Nov 04
High number of new directors Oct 31
Investor sentiment deteriorated over the past week Oct 24
Price target decreased to US$10.57 Oct 04 Shareholder Returns CLNN US Biotechs US Market 7D 0.4% -3.8% -2.7% 1Y -18.6% -2.6% 23.4%
See full shareholder returns
Return vs Industry: CLNN underperformed the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: CLNN underperformed the US Market which returned 23.4% over the past year.
Price Volatility Is CLNN's price volatile compared to industry and market? CLNN volatility CLNN Average Weekly Movement 11.1% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 16.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: CLNN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CLNN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company Founded Employees CEO Website n/a 84 Rob Etherington clene.com
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain’s energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson’s Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution.
Show more Clene Inc. Fundamentals Summary How do Clene's earnings and revenue compare to its market cap? CLNN fundamental statistics Market cap US$35.11m Earnings (TTM ) -US$36.02m Revenue (TTM ) US$421.00k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) CLNN income statement (TTM ) Revenue US$421.00k Cost of Revenue US$90.00k Gross Profit US$331.00k Other Expenses US$36.36m Earnings -US$36.02m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -4.51 Gross Margin 78.62% Net Profit Margin -8,556.77% Debt/Equity Ratio -431.9%
How did CLNN perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 00:11 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Clene Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Bruce Jackson Benchmark Company Sumant Satchidanand Kulkarni Canaccord Genuity Charles Duncan Cantor Fitzgerald & Co.
Show 6 more analysts 
